Leap Therapeutics Q3 net loss $18.2M; DKN-01 CRC enrollment complete, data mid-2025

CYPHERPUNK TECHNOLOGIES INC.

2024-Q3 EPS reported -$1.44

Net loss of $18.2M for Q3 2024, up from $13.7M YoY, driven by higher R&D expenses.
R&D expenses $14.9M (vs $11.5M); G&A $2.9M (vs $3.3M); cash $62.8M at Sept 30, 2024.
Completed enrollment (188 patients) in Part B of DeFianCe study (DKN-01 in CRC); initial data expected mid-2025.
DisTinGuish study (GEJ/gastric) Part C follow-up ongoing; initial data late 2024 or early 2025.
Initiated development of FL-501, an anti-GDF-15 antibody for cachexia; promising preclinical data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.